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Abstract
Purpose The Ki67 proliferation index is a prognostic and predictive marker in breast cancer. Manual scoring is prone to 
inter- and intra-observer variability. The aims of this study were to clinically validate digital image analysis (DIA) of Ki67 
using virtual dual staining (VDS) on whole tissue sections and to assess inter-platform agreement between two independent 
DIA platforms.
Methods Serial whole tissue sections of 154 consecutive invasive breast carcinomas were stained for Ki67 and cytokeratin 
8/18 with immunohistochemistry in a clinical setting. Ki67 proliferation index was determined using two independent DIA 
platforms, implementing VDS to identify tumor tissue. Manual Ki67 score was determined using a standardized manual 
counting protocol. Inter-observer agreement between manual and DIA scores and inter-platform agreement between both 
DIA platforms were determined and calculated using Spearman’s correlation coefficients. Correlations and agreement were 
assessed with scatterplots and Bland–Altman plots.
Results Spearman’s correlation coefficients were 0.94 (p < 0.001) for inter-observer agreement between manual counting 
and platform A, 0.93 (p < 0.001) between manual counting and platform B, and 0.96 (p < 0.001) for inter-platform agree-
ment. Scatterplots and Bland–Altman plots revealed no skewness within specific data ranges. In the few cases with ≥ 10% 
difference between manual counting and DIA, results by both platforms were similar.
Conclusions DIA using VDS is an accurate method to determine the Ki67 proliferation index in breast cancer, as an alterna-
tive to manual scoring of whole sections in clinical practice. Inter-platform agreement between two different DIA platforms 
was excellent, suggesting vendor-independent clinical implementability.
Keywords Breast cancer · Ki67 proliferation index · Immunohistochemistry (IHC) · Virtual dual staining · Digital image 
analysis (DIA) · Inter-platform agreement
Abbreviations
DIA  Digital image analysis
IHC  Immunohistochemistry
ROI  Region of interest
TMA  Tissue microarray
VDS  Virtual dual staining
Introduction
Breast cancer is the most common type of cancer among 
women worldwide, and one of the leading causes of 
cancer-related death [1]. A diversity of histological and 
molecular parameters exists to predict prognosis and sur-
vival [2]. Immunohistochemistry for Ki67 (MKI67), a 
nuclear antigen which is present in all but the G0 phase of 
the cell cycle and therefore expressed in proliferating cells, 
can be used to determine tumor proliferation index [3]. 
Ki67 is a prognostic and predictive marker in breast cancer 
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patients used in both clinical practice and clinical trials 
[4, 5]. However, Ki67 staining is subject to intra-tumoral 
heterogeneity and Ki67 scoring is prone to inter- and intra-
observer variability, especially with ‘eyeballing’ [6–10]. 
Manual counting is time-consuming as at least 500–1000 
cells have to be counted to achieve acceptable error rates 
and to correct for heterogeneity [4, 5].
Recently, digital image analysis (DIA) has emerged 
as a reproducible and less time-consuming alternative to 
manual scoring of Ki67 in breast cancer, which potentially 
offers a standardized diagnostic solution [4, 5, 11]. Several 
studies report high concordance between manual scoring 
and DIA [12–14]. However, these studies focus mainly 
on small tumor areas, either tissue microarrays (TMAs) 
or specific regions of interest (ROIs) within larger sec-
tions, which does not take into account intra-tumoral Ki67 
heterogeneity. In clinical practice, Ki67 scoring is often 
performed on whole tissue sections, which is also pro-
moted by the International Ki67 in Breast Cancer Working 
Group, who recommends ‘an approach that assesses the 
whole section’ [5]. For DIA on Ki67-stained sections, the 
distinction between tumor and non-tumor tissue is vital 
to avoid over- or underestimation of Ki67 proliferation 
index due to counting of non-neoplastic cells. However, 
manual tumor outlining in the large tissue areas of whole 
tumor sections is impractical, and tissue classifiers based 
on morphological characteristics can be relatively inac-
curate [15–17]. Physical dual staining offers a possible 
solution, by identifying tumor with cytokeratin in addition 
to Ki67 on the same section, but DIA on this method is 
impaired by overlapping chromogens and pixel intensities 
of both stains [18, 19]. A novel method which circumvents 
this issue is virtual dual staining (VDS), in which serial 
sections stained with Ki67 and cytokeratin are digitally 
aligned [14, 15]
Studies comparing manual scoring and DIA have used 
different platforms by various vendors, which have unique 
image analysis algorithms to determine Ki67 prolifera-
tion index [12–17]. As these algorithms have different 
approaches to classify tissue and cellular components, 
inter-platform variability may be expected [15, 20]. To 
the best of our knowledge, all studies up to this date have 
implemented only one DIA platform per study and there-
fore have not examined inter-platform agreement.
The aims of this study were to validate DIA of Ki67 in 
breast carcinomas in a clinical setting using VDS on whole 
sections by comparing a manual whole section scoring 
protocol with automated scoring, and to assess inter-plat-
form agreement between two independent DIA platforms.
Materials and methods
Resection specimens of 154 consecutive primary invasive 
breast carcinomas treated in the University Medical Center 
Groningen (The Netherlands) between August 2015 and 
February 2017 were prospectively included. Patient and 
tumor characteristics are shown in Table 1.
Immunohistochemistry
Three-micrometer serial sections were cut from forma-
lin-fixed paraffin-embedded tumor blocks during normal 
clinical workflow. Adjacent sections were stained for Ki67 
Table 1  Patient and tumor characteristics
DIA digital image analysis, ER estrogen receptor, PR progesterone 
receptor, HER2 human epidermal growth factor 2
a 37 cases were excluded from further analysis due to misalignment of 
the virtual dual staining
All cases, n (%) DIA  casesa, 
n (%)
Total 154 (100) 117 (100)
Gender
 Female 151 (98.1) 115 (98.3)
 Male 3 (1.9) 2 (1.7)
Age (years)
 < 60 74 (48.1) 56 (47.9)
 ≥ 60 80 (51.9) 61 (52.1)
 Mean 60.4 60.5
Histologic type
 Ductal/no special type 132 (85.7) 101 (86.3)
 Lobular 22 (14.3) 16 (13.7)
Histologic grade
 G1 37 (24.0) 28 (23.9)
 G2 75 (48.7) 57 (48.7)
 G3 42 (27.3) 32 (27.4)
Tumor diameter (cm)
 ≤ 2 102 (66.2) 80 (68.4)
 > 2 and ≤ 5 42 (27.3) 30 (25.6)
 > 5 10 (6.5) 7 (6.0)
 Mean 2.1 2.0
ER
 Positive 133 (86.4) 100 (85.5)
 Negative 21 (13.6) 17 (14.5)
PR
 Positive 118 (76.6) 92 (78.6)
 Negative 36 (23.4) 25 (21.4)
HER2
 Positive 15 (9.7) 9 (7.7)
 Negative 137 (89.0) 106 (90.6)
 Equivocal 2 (1.3) 2 (1.7)
35Breast Cancer Research and Treatment (2018) 169:33–42 
1 3
(CONFIRM anti-Ki-67 (30-9) rabbit monoclonal antibody, 
Ventana Medical Systems, Illkirch, France) and cytokeratin 
8/18 (CK8/18 (B22.1 & B23.1) mouse monoclonal antibody, 
Ventana Medical Systems) on a Ventana BenchMark Ultra 
immunostainer (Ventana Medical Systems). Antibodies were 
pre-diluted by the manufacturer and staining was performed 
following the manufacturer’s protocols. Antigen retrieval 
times were 36 min for Ki67 and 64 min for CK8/18 (both 
using Cell Conditioning 1, pH 9, Ventana Medical Systems). 
Antibody incubation times were 28 min for Ki67 and 32 min 
for CK8/18. Antibody amplification was applied for CK8/18 
(not for Ki67), using the Ventana Amplification Kit (Ventana 
Medical Systems).
Image acquisition and DIA platforms
Digital images were acquired by scanning the glass slides 
in a Philips Ultra Fast Scanner 1.6 (Philips, Eindhoven, The 
Netherlands) with a 40× magnification lens, using a sin-
gle focus layer without Z-stacking. Tissue detection with 
focus points was applied automatically to obtain the optimal 
image. Digitalized slides were stored on a centralized image 
server and a direct link with this server was established in 
both DIA platforms. The DIA platforms were Visiopharm 
Integrator System (VIS) platform version 6.9.0.2779 (Visi-
opharm, Hørsholm, Denmark) and HALO platform ver-
sion 2.0.1061 (Indica Labs, Corrales, New Mexico, United 
States).
Manual counting
Manual counting of Ki67 proliferation index was performed 
by a resident pathologist (TK), using a protocol based on the 
‘whole section scoring protocol’ by the International Ki67 in 
Breast Carcinoma Working Group, with ROIs to represent 
the spectrum of staining in the whole section [5, 8]. On the 
digital image, three 0.500 mm2 ROIs were annotated within 
areas with high, medium, and low proliferation, respectively. 
If only two area types were present, two of three ROIs were 
selected in the area comprising the most common prolifera-
tion rate. Of the three ROIs, at least one ROI was selected 
centrally and at least one peripherally (i.e., the invasive 
edge) in the tumor. One of the ROIs was a hot spot, if pre-
sent. In each ROI, 200 cells were counted in a ‘typewriter’ 
pattern (i.e., counting in rows within the ROI, from top to 
bottom, to assure a reproducible counting method) [7, 8]. 
Any definite brown nuclear staining was considered positive. 
Ki67 proliferation index representative of the whole tumor 
section was then calculated by dividing the number of Ki67 
positive cells by the total number of counted cells (600 cells 
for each case).
Digital image analysis
A training set of 20 randomly selected breast carcinoma cases 
obtained between January and August 2015, which were 
identically handled and stained but not included in the current 
study, was used to calibrate tissue classification by CK8/18 
in VDS and nuclear classification of Ki67 in both DIA plat-
forms. Calibration was done in close collaboration with both 
platform vendors, independently of each other. In both plat-
forms, VDS was applied to digitally align corresponding 
Ki67- and cytokeratin-stained sections. During this process, 
the algorithms automatically perform distortion and rotation 
modifications to eliminate small differences due to tissue 
and section processing. Alignment was verified visually for 
each case, and misaligned cases were excluded from further 
analysis. The algorithms were then set to use the cytokeratin-
stained area as the tumor classifier on the Ki67-stained section. 
Within the whole tissue section, the complete invasive tumor 
area was annotated. If present, large areas of carcinoma in situ, 
pre-existent epithelium, and tissue or staining artifacts were 
excluded. Ki67 positivity was analyzed with nuclear classifi-
cation algorithms which detect nuclei by morphological form 
and size and classify these as positive or negative based on 
pixel color and intensity. In both platforms, named ‘platform 
A’ and ‘platform B’ henceforth, Ki67 proliferation index was 
calculated by dividing the number of Ki67 positive cells by 
the total number of positive and negative cells within the area 
classified as tumor by VDS. In cases with a ≥ 10% Ki67 differ-
ence by DIA versus manual counting and intra-tumoral Ki67 
heterogeneity, additional DIA was performed on the manu-
ally counted ROIs only, to evaluate representativeness of these 
ROIs for the whole tumor.
Statistical analysis
Spearman’s correlation coefficients were calculated for 
inter-observer agreement between Ki67 proliferation index 
by manual counting and by one of the two DIA platforms, 
as well as for inter-platform agreement. Scatterplots and 
Bland–Altman plots were created to assess inter-observer 
and inter-platform correlation and agreement in relation to 
data ranges. Plots were created and statistical analysis was 
performed using IBM SPSS Statistics for Windows ver-
sion 23.0.0.3 (SPSS, Chicago, Illinois, United States). All 
testing was two sided. Values of p < 0.05 were considered 
significant.
Results
Of the 154 cases included, VDS failed in 37 cases (24%) 
because of alignment issues due to relative folding or twist-
ing of tissue, or because sections were not properly cut in 
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serial order. VDS alignment was not influenced by CK8/18 
staining or tumor size. Of these 37 cases, 32 were misaligned 
in both DIA platforms, 3 cases were misaligned in only one 
platform (as the other platform’s algorithm was able to cor-
rect the relative twisting), and 2 cases could not be aligned 
by one platform as the stains were mirrored. Therefore, fur-
ther analysis was performed on 117 cases.
Correlation of manual counting and DIA
Manual and digital cell count profile and Ki67 prolifera-
tion index are displayed in Table 2. DIA is illustrated in 
Fig. 1. Ki67 scores were slightly higher by manual counting 
than by DIA; mean 19.5% versus 18.3–18.4% and median 
13.5% versus 12.2–12.6%. Scatterplots and Bland–Altman 
plots of manual counting compared to both DIA platforms 
as well as between platforms are displayed in Fig. 2. There 
was no skewness within specific data ranges. Correlation 
for inter-observer agreement between manual counting and 
DIA was high: Spearman’s correlation coefficients were 0.94 
(p < 0.001) for manual counting compared to platform A and 
0.93 (p < 0.001) for manual counting compared to platform 
B. Correlation for inter-platform agreement between plat-
form A and platform B was even higher, with a Spearman’s 
correlation coefficient of 0.96 (p < 0.001).
Cases with ≥ 10% Ki67 difference
Ten of all 117 cases (8.5%) showed a difference in Ki67 
proliferation index of ≥ 10% by DIA compared to manual 
counting, as shown in Table 3 and illustrated in Fig. 3. Only 
2 cases had differences of > 13%. In 5 of the 10 cases, dif-
ferences between manual counting and DIA were due to 
intra-tumoral Ki67 heterogeneity. When DIA was done 
on the manually counted ROIs only (instead of the whole 
tumor), differences were well below 10%. In the other 5 
cases, the difference was due to tumor morphology or stain-
ing artifacts. Interestingly, differences between both DIA 
platforms were < 5% in the majority of cases (8 out of 10). 
Only one case had a ≥ 10% (10.2%) difference between plat-
forms, due to hematoxylin overstaining which led to positive 
classification of Ki67 negative cells in platform A but not in 
platform B. In another case, artifactual cytoplasmic staining 
was erroneously recognized as positive nuclear staining by 
platform B but not by platform A (6.2% difference).
Clinical context
The clinically relevant Ki67 cut-off is 20%, as defined by 
the St. Gallen criteria [21]. When this cut-off was applied in 
our study, discordance of tumor subtype classification due 
to Ki67 score by DIA versus manual counting occurred in 4 
cases (3.4%) with platform A and 2 cases (1.7%) with plat-
form B. Of these cases, one was among the cases with ≥ 10% 
difference discussed previously. All of the remaining cases 
were just above or just below the 20% cut-off with differ-
ences of 3.9% at most, illustrating a small margin of error 
(results by both platforms were similar). The degree of Ki67 
differences between different counting methods in cases with 
Ki67 between 15 and 25% (near the 20% cut-off) is displayed 
in Supplementary Table 1. Clinicopathological characteris-
tics of these cases were similar to those of the total study 
population (Supplementary Table 2).
Discussion
The aims of this study were to clinically validate DIA of 
Ki67 using VDS on whole tissue breast carcinoma sections, 
and to assess inter-platform agreement between two inde-
pendent DIA platforms. We found high inter-observer agree-
ment between manual counting and DIA, and even higher 
inter-platform agreement.
Correlations in studies comparing manual scoring with 
DIA vary between 0.89 and 0.97 [12–14]. In the cur-
rent study, Spearman’s correlation coefficients were 0.94 
(p < 0.001) and 0.93 (p < 0.001) between manual counting 
versus platform A and platform B, respectively, which is in 
line with these studies. Only one study implemented VDS, 
with an intraclass correlation coefficient of 0.97 between 
manual counting and DIA [14]. However, that study used 
TMAs and thereby preselected smaller areas of the whole 
Table 2  Cell count profile and 
Ki67 proliferation indexes by 
manual counting and digital 
image analysis
Mean Min Q1 Q2 (median) Q3 Max
Cells counted
 Manual 600 600 600 600 600 600
 Platform A 189,086 3853 53,524 131,043 281,928 715,525
 Platform B 206,154 6010 63,632 154,386 299,081 889,638
Ki67, %
 Manual 19.5 0.0 7.8 13.5 26.0 84.0
 Platform A 18.4 0.1 7.5 12.2 30.0 86.4
 Platform B 18.3 0.1 7.5 12.6 23.1 82.7
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tumor. In clinical practice, Ki67 is often scored on whole 
sections, as is recommended by the International Ki67 
Working Group [5]. In our study, a manual counting pro-
tocol based on the ‘whole section scoring protocol’ by this 
Working Group was highly concordant with DIA on whole 
sections. As such, we have confirmed that VDS is an accu-
rate method to perform DIA of Ki67 on whole sections and 
can be used in clinical practice.
Of the initial 154 cases included in our study, a large 
number (37 cases; 24%) was excluded due to VDS failure, 
which occurred in both platforms. For successful VDS 
alignment, the Ki67- and cytokeratin-stained sections must 
be identical and accurate serial sectioning is essential. 
Additionally, folding or twisting of one of the sections can 
cause VDS misalignment. As such, it is crucial that labora-
tory technicians responsible for the preparation of the slides 
are properly instructed and trained. For this study, labora-
tory technicians did not receive specific instructions on the 
necessity of careful stretching and serial sectioning, which 
could be the cause of the large number of misaligned cases. 
For clinical implementation of VDS, we therefore recom-
mend specific instruction and training courses for laboratory 
technicians on the effects of inaccurately cut and mounted 
sections.
Inter-platform variability between different DIA platforms 
may be expected as tissue morphology, cellular features, 
Fig. 1  Digital image analysis of Ki67 with virtual dual staining. Cor-
responding cytokeratin (a) and Ki67 (b) stains are virtually aligned 
and Ki67 nuclear classification is determined among the cells in the 
area classified as tumor, shown in platform A (c, d) and platform B 
(e, f). Images at 200× magnification
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and staining patterns are handled differently depending on 
the platform’s algorithm [15, 20]. In clinical practice, this 
could lead to inconsistency of Ki67 scores when different 
platforms are used to perform DIA. To the best of our knowl-
edge, the current study is the first to address inter-platform 
agreement on one set of tumors. Inter-platform agreement 
Fig. 2  Scatterplots with correlation coefficients (left) and Bland–Alt-
man plots of agreement (right) between whole tumor Ki67 prolifera-
tion index by manual counting versus platform A (upper row), man-
ual counting versus platform B (middle row), and platform A versus 
platform B (lower row)
39Breast Cancer Research and Treatment (2018) 169:33–42 
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was very high, with a Spearman’s correlation coefficient of 
0.96. This shows that DIA is reproducible among different 
platforms, and therefore a clinical pathology laboratory is 
not bound to a specific DIA platform or vendor, as long as 
the algorithm is calibrated and validated in close collabora-
tion with the platform vendor.
In 5 cases, there was a ≥ 10% difference in Ki67 prolifera-
tion index between DIA and manual counting due to tumor 
morphology or staining artifacts. Results by both platforms 
were similar in these cases, illustrating that both platforms 
handle troublesome cases in a similar way. We recommend 
that after analysis, a quick visual check of the results by a 
clinical pathologist should always be performed.
Intra-tumoral heterogeneity is a known occurrence in 
Ki67 stains [4, 16, 22, 23]. The manual counting protocol 
used in our study compensated for heterogeneity in most 
cases, yet there were 5 cases with a ≥ 10% difference due 
to heterogeneity. In these cases, we performed additional 
DIA on the manually counted ROIs (instead of the whole 
tumor). In that analysis, differences became well below 10%, 
showing that the manually selected ROIs were inadequately 
representative for the whole tumor in these cases (Table 3).
In a clinical context, Ki67 can be used in the distinction 
of intrinsic tumor subtypes (luminal A or luminal B). Previ-
ously, DIA of the concerning surrogate biomarkers (ER, PR, 
HER2 and Ki67) was shown to be prognostic superior to 
manual scoring [15]. According to the St. Gallen criteria, the 
clinically relevant Ki67 cut-off is 20% [21]. When this cut-
off was applied for Ki67 by DIA versus manual counting in 
our study, there was discordance of tumor subtype classifica-
tion in only a few cases. Additionally, the difference between 
counting methods (Supplementary Table 1) was < 5% in 
the majority of all DIA cases as well as in Ki67 15–25% 
subgroups (near the 20% cut-off). However, even a small 
discrepancy can make the difference between subtyping in 
cases near the 20% cut-off. Whether manual counting or 
DIA should be the ‘gold standard’ in these cases is subject 
to debate; most studies have correlated clinical significance 
with manual counting, but others have shown that DIA is 
prognostically stronger [5, 11, 15]. With regard to the St. 
Gallen criteria, Ki67 is only of importance in tumors which 
are ER positive, PR positive, and HER2 negative, especially 
in low-grade tumors of small size [21]. However, clinico-
pathologic characteristics of cases near the 20% cut-off were 
similar to that of our total study population (Supplementary 
Table 2), with possibly a slightly higher ER-positivity and 
HER2-positivity rates. As such, no specific clinicopathologi-
cal characteristic is predictive of this Ki67 subgroup, though 
the clinical relevance of Ki67 in ER-negative, PR-negative, 
and/or HER2-positive tumors could be limited.
Calibration and validation are vital to the success of 
DIA [9]. Calibration can be challenging, and it is impor-
tant to realize that the image analysis algorithms of both 
platforms used in our study were calibrated on our labo-
ratory stains and scans, in close collaboration with the 
platform vendors. This collaboration is important, as the 
pathologist has the clinical expertise, whereas the platform 
vendor has the technical expertise. Differences in proto-
cols and equipment among laboratories but also within one 
laboratory necessitate proper and continuous calibration 
and validation, as differences in staining methodology and 
materials can lead to variable texture and color nuances 
Table 3  Cases with ≥ 10% difference of Ki67 proliferation index by manual counting and DIA (total n = 117)
DIA digital image analysis, ROI region of interest
a Difference with manual Ki67 score, ≥ 10% differences highlighted in bold
b Difference with manual Ki67 score when DIA was performed on the manually counted ROIs instead of on the whole tumor, in cases with Ki67 
heterogeneity
c Only this single case had a ≥ 10% difference between platform A and platform B
Case Manual Ki67 % Platform 
A Ki67 % 
(difference)a











1 5.4 12.2 (6.8) 18.4 (13.0) 6.2 Cytoplasmic Ki67 staining artifacts – –
2 8.0 20.2 (12.2) 10.0 (2.0) 10.2c Nuclear hematoxylin overstaining – –
3 11.5 21.8 (10.3) 19.1 (7.6) 2.7 Ki67 heterogeneity 17.7 (6.2) 15.5 (4.0)
4 30.0 18.9 (11.1) 17.0 (13.0) 1.9 Ki67 heterogeneity 30.7 (0.7) 31.1 (1.1)
5 35.7 25.9 (9.8) 25.3 (10.4) 0.6 Ki67 heterogeneity 29.9 (5.8) 29.8 (5.9)
6 40.0 71.2 (31.2) 74.7 (34.7) 3.5 Cell clustering and nuclear overlap – –
7 55.5 43.3 (12.2) 48.1 (7.4) 4.8 Cell clustering and nuclear overlap – –
8 58.9 48.9 (10.0) 50.6 (8.3) 1.7 Ki67 heterogeneity 53.2 (5.7) 53.5 (5.4)
9 64.4 77.0 (12.6) 74.4 (10.0) 2.6 Ki67 heterogeneity 70.0 (5.6) 67.1 (2.7)
10 76.4 50.8 (25.6) 51.1 (25.3) 0.3 Clear cell morphology of the tumor – –
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which can influence DIA algorithms [14]. Further stud-
ies could investigate the performance of DIA with regard 
to inter-laboratory variability on identical sets of tumors. 
Additionally, inter-platform agreement between other 
platforms than the two included in this study should be 
investigated.
A last point of interest is the cost of DIA. Initially, DIA 
would seem expensive, as it requires a scanner for digitaliza-
tion of the images, DIA software, and a technician to carry 
out the analysis. However, an increasing amount of modern 
pathology laboratories are incorporating digital pathology 
in their diagnostic workflow [24]. In addition to being more 
Fig. 3  Cases with ≥  10% difference in Ki67 proliferation index 
between digital image analysis and manual counting due to tumor 
morphology or staining artifacts. One case had clear cell morphology, 
causing erroneous tumor classification (a–c). Two cases had nuclear 
overlap and cell clustering (d), causing misclassification of Ki67 both 
by platform A (e) and platform B (f). In one case, artifactual cyto-
plasmic Ki67 staining (g) was correctly handled by platform A (h) 
but was classified as positive nuclear staining by platform B (i). One 
case with hematoxylin overstaining (j) led to false-positive classifica-
tion of nuclei by platform A (k) but not by platform B (l). Images at 
200× magnification
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reproducible, DIA can replace time-consuming manual 
counting of Ki67, saving pathologists time.
In conclusion, we have shown that DIA using VDS is an 
accurate method to determine Ki67 proliferation index on 
whole sections of invasive breast carcinomas. For clinical 
implementation, proper training of laboratory technicians 
responsible for the section preparation is crucial to prevent 
failure of VDS alignment. DIA of Ki67 offers an objective 
alternative to manual Ki67 counting and has high inter-plat-
form agreement, suggesting that it is clinically implementa-
ble independent of a specific platform vendor.
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